Interferon-? Inhibits Ebola Virus Infection

Rhein, Bethany A.; Powers, Linda S.; Rogers, Kai; Anantpadma, Manu; Singh, Brajesh K.; Sakurai, Yasuteru; Bair, Thomas; Miller-Hunt, Catherine; Sinn, Patrick; Davey, Robert A.; Monick, Martha M.; Maury, Wendy

The production of recombinant, replication-competent vesicular stomatitis virus expressing eGFP and EBOV GP in place of the G glycoprotein (EBOV GP/rVSV) was performed as previously described [23, 25, 81] . The EBOV GP used in these studies was a GP lacking the mucin domain of GP1, which confers the same tropism as the full-length EBOV GP and produces higher titers [82] [83] [84] . EBOV GP/rVSV stocks were produced by infecting Vero cells at a low multiplicity of infection (~0.001) and collecting supernatants 48 hours following infection. Virus-containing supernatants were filtered through a 0.45 μm filter and stored at -80°C. EBOV GP/rVSV for mouse studies was concentrated by centrifugation at 7,000 x g at 4°C overnight. The virus pellet was resuspended and centrifuged through a 20% sucrose cushion by ultracentrifugation at 26,000 rpm for 2 hours at 4°C. The pellet was resuspended in PBS, aliquoted, and frozen at -80°C until use.